• Recruiting

NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial

Updated: May 24

NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial


scope trial selinexor

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial


This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple myeloma that has come back (relapsed) and does not respond to treatment with proteasome inhibitors and immunomodulatory drugs (refractory). Selinexor is an oral agent that blocks a protein called Exportin 1 (XPO1 or CRM1) that is abundant in a wide variety of cancers, including multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pomalidomide may stop the growth of blood vessels, stimulate the immune system, and kill cancer cells. Anti-inflammatory drugs, such as dexamethasone may lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The addition of selinexor may allow better control of relapsed refractory multiple myeloma than is possible with pomalidomide and dexamethasone with or without carfilzomib.


Sponsor:

Mayo Clinic


Collaborator:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT04764942


Official Title: Phase 1/2 Trial of Selinexor in Combination With Pomalidomide and Dexamethasone ± Carfilzomib for Patients With Proteasome-Inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma (SCOPE)


First Posted: February 21, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Pomalidomide

Other: Quality-of-Life Assessment

Other: Questionnaire Administration

Drug: Selinexor

 

Seli - Pd

Seli - KPd

 

Location

United States, Minnesota





Posts Archive